Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
# {7 D- K0 E# w" P& a2 K5 u- [8 r- Z9 G! Y
! C! `- v& a( o6 r- h) R: oSub-category:# ?" q3 [- ~ B+ I% i: `
Molecular Targets 7 z1 ?2 e7 D) }, V* Q. e
# `' r Q ^/ o5 N. A/ _6 N% }, K% c: r5 A9 W, C) }& H8 {9 x
Category:
) v$ M- X8 R: w+ LTumor Biology
$ o7 L9 ]/ l% G! _3 K
6 Y. B( M8 ]/ c& i6 l8 g0 C$ e/ A) y& O) Q0 f3 v+ R1 m
Meeting:
5 C8 i. K4 ]0 i7 j- B4 b2011 ASCO Annual Meeting
" u9 }* U( `7 p9 N3 d, F* F! T- i0 V8 M
% e/ z3 ~" C( o3 M
Session Type and Session Title:
4 t6 T0 e6 F" D, [Poster Discussion Session, Tumor Biology
1 U K8 N1 L8 j: c
) s7 d$ h0 g4 T( P& Q5 x/ H3 d l0 y5 a, ?6 J# X! @
Abstract No:
: N! A4 b# {( j* B9 M10517
; I6 d8 I+ w% O$ E4 R0 _6 S/ Y$ H$ u9 B+ { g$ F
9 c( w4 o( k& ^( V- {7 \) U0 N1 bCitation:, u) V% t' ?/ B! x8 @
J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 S* `* P4 k, _ Y+ p1 |/ N/ D# F1 ~* s# J
) F+ W' m7 ]! E- b4 ]Author(s):; q% r- k& C# D1 H! g3 X* d: J9 O
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) {- J: s1 d7 _8 J5 Q: c9 ?
" G2 T9 ~- f- X
: W2 w9 W M% ]. m3 ]; c: R, [5 J3 L0 h6 b" F
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 B" G, b/ J$ Z' c% z/ E6 T
6 s, Z& _0 h# h$ e4 e* IAbstract Disclosures
+ C2 K: h. g8 D4 |' f# c* {% L: d# I7 d" J9 A; Q: x: A0 K, }
Abstract:
+ h9 s0 Q$ G0 r) W1 h- ?, n- L7 G3 T) L2 R
* k- ]7 ~% Z& b9 W p( D
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
3 ^2 ^8 u3 D7 ]: E3 Z' g
; z; r1 t' {0 {1 p. `- |
1 P8 I+ U: z, I; H |
【安心服药指南】MET抑制剂不良反应
作者：seacat
很多正在使用 MET 靶向药的患者，都会担心一个问题：
“这个药物疗效的
妈妈抗肺癌4年啦，我们的4点避“坑”
讲述者：Maggie整理者：pear
四年前，妈妈被确诊为肺腺癌晚期。抗癌伊始我们就经历诸
总生存期达26.5个月！肺癌靶向治疗耐
作者：Tony
EGFR-TKI耐药后的治疗选择一直是困扰肺癌患者的重要难题。如今，我们对EGF
肺动脉阻塞，胸闷气短，下一步如何处
请教各位有经验的友友们，目前这种情况如何处理？现在气短的厉害，已无法正常行走，走
求助：1a1实体型低分化alk突变复发概
背景：35岁男性，无吸烟史，有熬夜习惯，检查前曾参与新房装修。24年7月底体检第一次
' h! _# \9 O) D' z! v" J" g
显身卡
